Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allantoin - Amicus Therapeutics

Next Previous
Drug Profile

Allantoin - Amicus Therapeutics

Alternative Names: SD-101 - Amicus Therapeutics; Zorblisa

Latest Information Update: 17 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scioderm
  • Developer Amicus Therapeutics
  • Class Anti-inflammatories; Antiacnes; Antipsoriatics; Hydantoins; Imidazolidines; Keratolytics; Small molecules; Urea compounds
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic foot ulcer; Epidermolysis bullosa; Psoriasis

Most Recent Events

  • 03 Sep 2018 Amicus Therapeutics terminates an extension trial in Epidermolysis bullosa in USA, Australia, Austria, France, Germany, Israel, Lithuania, Netherlands, Poland, Serbia, Spain, and the United Kingdom, due to GMP deficiencies identified during an FDA inspection at the site of the manufacturer (NCT02090283)
  • 13 Sep 2017 Discontinued - Phase-III for Epidermolysis bullosa in Serbia, Belgium, Israel, Lithuania, Spain, Australia, Poland, United Kingdom, Germany, France, Italy, Netherlands and Austria (Topical)
  • 13 Sep 2017 Discontinued - Preclinical for Diabetic foot ulcer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top